Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.

  title={Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.},
  author={James D. Chalmers and Charles S. Haworth and Mark L. Metersky and Michael R. Loebinger and Francesco Blasi and Oriol Sibila and Anne E. O'donnell and Eugene J. Sullivan and Kevin C. Mange and Carlos Fernandez and Jun Zou and Charles L. Daley},
  journal={The New England journal of medicine},
BACKGROUND Patients with bronchiectasis have frequent exacerbations that are thought to be related to neutrophilic inflammation. The activity and quantity of neutrophil serine proteases, including neutrophil elastase, are increased in the sputum of patients with bronchiectasis at baseline and increase further during exacerbations. Brensocatib (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neutrophil serine proteases… 

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

The PK/PD evaluation demonstrated the clinically meaningful relationship between suppression of neutrophil elastase activity and reduction in exacerbations in brensocatib-treated patients with NCFBE, supporting further development of brenSocatib for bronchiectasis.

Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults

The results from this study demonstrate that brensocatib can be administered with or without food and that dose adjustment is unnecessary for Japanese patients when receiving brenSocatib treatment.

Protease–Antiprotease Imbalance in Bronchiectasis

The identification of different targets of therapy within the protease–antiprotease balance contributes to a precision medicine approach in bronchiectasis and eventually interrupts and disrupts the vicious vortex which characterizes the disease.

Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism

It is proposed that targeting metabolism could theoretically reverse neutrophil dysfunction and dysregulated inflammation and the need for a new immunomodulatory, rather than anti-inflammatory, approach to enhance bacterial clearance and reduce bronchiectasis disease severity is proposed.

Bronchiectasis enters the inflammation era

It is found that increased sputum NET complexes were associated with disease severity, reduced quality of life, severe exacerbations and mortality, and found that NETs are likely to be the primary mechanism by which harmful neutrophil serine proteases such as elastase are released and damage the airway.

Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study

Almost one out of five patients with BE were prescribed ICS despite having no concomitant diagnosis of asthma or COPD, and ICS treatment was associated with higher morbidity and mortality, though causation is difficult to establish.

The emerging role of proteases in α1-antitrypsin deficiency and beyond

A new framework of understanding defined by protease-driven endotypes of disease which may lead to new opportunities for precision medicine is considered, including the contribution to distinct phenotypes of the disease.

Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management.

Various long-term therapies, including antimicrobial and anti-inflammatory strategies, have been proven effective in reducing the frequency of PEx, leading to a recommendation for the use of these strategies in people with frequent PEx.